NASDAQ · GUTS
Fractyl Health, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for GUTS: Nov 11, 2026
Fractyl Health, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-1.59. The reported EPS for the same quarter last year was $-4.2.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-1.59 | $-1.56 | $-1.62 | 2 |
| Dec 2026 | $-1.32 | $-1.32 | $-1.32 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · NASDAQ.com · MarketBeat · RTTNews- Fintel · Oct 23, 4:42 AM EDTFractyl Health Consensus Price Target Increased by 917.27% to $46.07The average one-year price target for Fractyl Health (NASDAQGM:GUTS) has been revised to $46.07 / share. This is an increase of 917.27% from the prior estimate of $4.53 dated September 29, 2026. These figures represent aggregate analyst targets compiled by Fintel and do not cons
- Fintel · Oct 22, 10:24 AM EDTFractyl Health, Inc. Announces Strategic Reprioritization, 45% Workforce Reduction, and Leadership ChangesFractyl Health, Inc. adopted a plan on October 21, 2026, to sharpen its strategic focus on its Revita program in connection with a strategic reprioritization. As part of the plan, the company will reduce its workforce by approximately 45% of the Company’s current headcount,
- NASDAQ.com · Oct 16, 8:29 AM EDTPre-Market Most Active for Oct 16, 2026 : TSLL, GUTS, NOK, VRNS, TQQQ, TSLA, SPCX, STLA, IONQ, BAC, LYG, JOBYThe NASDAQ 100 Pre-Market Indicator is down -44.48 to 29,891.11. The total Pre-Market volume is currently 108,987,769 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X ETF (TSLL) is +0.6396 at $9.96, with 9,721,468 sha
- MarketBeat · Sep 1, 5:01 PM EDTFractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight MaintenanceFractyl Health (NASDAQ:GUTS) outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines. The company said Revita is de
- MarketBeat · Aug 14, 5:04 AM EDTFractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy TrialFractyl Health (NASDAQ:GUTS) is advancing two one-time treatment approaches intended to provide durable benefits for obesity, type 2 diabetes and related metabolic diseases, Chief Executive Officer Harith Rajagopalan said during a Canaccord discussion. The company’s lead program
- MarketBeat · Aug 10, 7:04 PM EDTFractyl Health Q2 Earnings Call HighlightsFractyl Health (NASDAQ:GUTS) said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to report pivotal trial data in early fourth-quarter 2026 and pursue a potential FDA
- RTTNews · Jul 18, 1:19 AM EDTWeekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data(RTTNews) – This week, the healthcare sector saw multiple U.S FDA and European Commission approvals, strategic licensing and M&A activity, as well as pivotal clinical trial readouts and regulatory setbacks.
- Zacks · Jul 16, 10:13 AM EDTFractyl Health Stock Up on Encouraging One-Year Revita Study ResultsGUTS' shares surge after Revita patients retain up to 84% of GLP-1-induced weight loss in a year, compared with 46% for sham patients.
- MarketBeat · Jul 15, 9:02 AM EDTFractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1sFractyl Health (NASDAQ:GUTS) reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its Revita procedure helped patients maintain a larger share of GLP-1-induced weight loss after discontinuing GLP-1 therapy compared with a sham procedure. On th
- RTTNews · Jul 15, 7:58 AM EDTFractyl's Revita Maintains Weight Loss Post GLP-1 Discontinuation; Stock Up(RTTNews) – Fractyl Health, Inc. (GUTS) announced positive one-year randomized data from the REMAIN-1 Midpoint Cohort, demonstrating that its Revita duodenal mucosal resurfacing (DMR) system can help maintain weight loss after stopping GLP-1 therapy.
- RTTNews · Jul 15, 6:37 AM EDTFractyl Health Reports Positive One-Year Revita Data From REMAIN-1 Midpoint Cohort(RTTNews) – Fractyl Health, Inc. (GUTS) on Wednesday reported positive one-year results from the Midpoint Cohort of its REMAIN-1 study, showing that its Revita DMR System significantly reduced weight regain in patients who had previously lost weight using GLP-1 therapy.
- RTTNews · Jun 4, 7:51 AM EDTFractyl Health Reports Positive One-Year REVEAL-1 Results For Revita(RTTNews) – Fractyl Health, Inc. (GUTS), a clinical-stage metabolic therapeutics company, on Thursday announced positive one-year results for Revita from its REVEAL-1 Cohort study.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Fractyl Health, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.